Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
NJqJnPh7MD150fMm
